TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Sponsor: Brown University + Incyte Corporation, Genentech, Inc.
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Complete response rate
Time frame: 3 months after starting therapy
Rate of toxicities
Time frame: From the day when informed consent is obtained until 90 days following the last administration of study treatment.
Secondary Endpoints
Progression-free survival
Event-free survival
Overall survival
Eligibility Criteria
Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent document and to comply with the study protocol procedures. 2. Age ≥18 years. 3. Histologically confirmed diagnosis of DLBCL, or HGBL, according to 5th edition WHO classification. Eligible WHO entities include: * Diffuse large B-cell lymphoma, not otherwise specified (NOS) * T-cell/histiocyte-rich large B-cell lymphoma * DLBCL/HGBL with MYC and BCL2 rearrangements * Large B-cell lymphoma with IRF4 rearrangement * HGBL with 11q aberration * EBV-positive diffuse large B-cell lymphoma * DLBCL associated with chronic inflammation * Primary large B-cell lymphoma of immune-privileged sites * Primary cutaneous DLBCL, leg type * Intravascular large B-cell lymphoma * Primary mediastinal large B-cell lymphoma * HGBL, NOS * Grade 3B follicular lymphoma. 4. FDG-avid disease by PET-CT Lugano criteria. 5. No prior systemic therapy for B-cell lymphoma, except for…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →